<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Anika Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/anika-therapeutics-inc</link>
<description>Latest news and press releases for Anika Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 11:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/anika-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835466078dffbe2df0e2f57.webp</url>
<title>Anika Therapeutics Inc</title>
<link>https://6ix.com/company/anika-therapeutics-inc</link>
</image>
<item>
<title>Anika Reports First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-first-quarter-2026-financial-results</guid>
<pubDate>Wed, 29 Apr 2026 11:05:00 GMT</pubDate>
<description>Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation generating early wins, delivering $4 million of adjusted EBITDA BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑i</description>
</item>
<item>
<title>Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/xilio-therapeutics-appoints-cheryl-r-blanchard-phd-to-its-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/xilio-therapeutics-appoints-cheryl-r-blanchard-phd-to-its-board-of-directors-1</guid>
<pubDate>Thu, 16 Apr 2026 11:30:00 GMT</pubDate>
<description>WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company’s board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. “Cheryl brings over three decades of leadership experience a</description>
</item>
<item>
<title>Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-to-issue-first-quarter-2026-financial-results-on-wednesday-april-29-2026</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-to-issue-first-quarter-2026-financial-results-on-wednesday-april-29-2026</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention</description>
</item>
<item>
<title>Telix Strengthens Board with Additional Director Appointments</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/telix-strengthens-board-with-additional-director-appointments-1</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/telix-strengthens-board-with-additional-director-appointments-1</guid>
<pubDate>Wed, 08 Apr 2026 22:44:00 GMT</pubDate>
<description>MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years’ experience in late-stage clinical development, commercialization and governance</description>
</item>
<item>
<title>Anika Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 12:05:00 GMT</pubDate>
<description>Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoart</description>
</item>
<item>
<title>Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-to-present-at-the-canaccord-genuity-2026-musculoskeletal-conference</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-to-present-at-the-canaccord-genuity-2026-musculoskeletal-conference</guid>
<pubDate>Wed, 18 Feb 2026 21:01:00 GMT</pubDate>
<description>BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the Even</description>
</item>
<item>
<title>Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-issue-fourth-quarter-end-210100271</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-issue-fourth-quarter-end-210100271</guid>
<pubDate>Thu, 12 Feb 2026 21:01:00 GMT</pubDate>
<description>BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-6</description>
</item>
<item>
<title>Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/lumicell-appoints-biotech-and-medtech-leader-cheryl-r-blanchard-phd-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/lumicell-appoints-biotech-and-medtech-leader-cheryl-r-blanchard-phd-to-board-of-directors</guid>
<pubDate>Wed, 04 Feb 2026 13:54:00 GMT</pubDate>
<description>Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies.</description>
</item>
<item>
<title>Anika Therapeutics Announces Leadership Transition</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-therapeutics-announces-leadership-transition-120000783</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-therapeutics-announces-leadership-transition-120000783</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice</description>
</item>
<item>
<title>Anika Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-third-quarter-2025-120500540</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-third-quarter-2025-120500540</guid>
<pubDate>Wed, 05 Nov 2025 12:05:00 GMT</pubDate>
<description>Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.</description>
</item>
<item>
<title>Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-therapeutics-reports-filing-final-120000728</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-therapeutics-reports-filing-final-120000728</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (PMA) for Hyalofast—its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate (BMAC) for treating articular cartilage defects in the knee. The Company also reported results from its U.S. pivotal Phase III FastTR</description>
</item>
<item>
<title>Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-issue-third-quarter-2025-200100256</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-issue-third-quarter-2025-200100256</guid>
<pubDate>Thu, 23 Oct 2025 20:01:00 GMT</pubDate>
<description>BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (i</description>
</item>
<item>
<title>Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-inducement-grants-under-090000163</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-inducement-grants-under-090000163</guid>
<pubDate>Fri, 05 Sep 2025 09:00:00 GMT</pubDate>
<description>BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on September 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $9.15, which equaled the closing price of common stock on the Nasdaq Global Select Market on</description>
</item>
<item>
<title>Anika Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-second-quarter-2025-110500231</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-second-quarter-2025-110500231</guid>
<pubDate>Wed, 30 Jul 2025 11:05:00 GMT</pubDate>
<description>Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module</description>
</item>
<item>
<title>Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-topline-results-u-110000295</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-topline-results-u-110000295</guid>
<pubDate>Wed, 30 Jul 2025 11:00:00 GMT</pubDate>
<description>Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvements over microfracture in pre-defined secondary endpoints and other measures that align with prior FDA approvals for cartilage repair products Hyalofast has been used to treat over 35,000 patients in more than 35 countries outside the U.S. since 200</description>
</item>
<item>
<title>Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-issue-second-quarter-2025-200100930</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-issue-second-quarter-2025-200100930</guid>
<pubDate>Wed, 16 Jul 2025 20:01:00 GMT</pubDate>
<description>BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (int</description>
</item>
<item>
<title>Anika Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-first-quarter-2025-110500208</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-first-quarter-2025-110500208</guid>
<pubDate>Fri, 09 May 2025 11:05:00 GMT</pubDate>
<description>First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solut</description>
</item>
<item>
<title>Anika to Participate in the Sidoti Virtual Investor Conference</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-participate-sidoti-virtual-investor-200100673</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-participate-sidoti-virtual-investor-200100673</guid>
<pubDate>Wed, 07 May 2025 20:01:00 GMT</pubDate>
<description>BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET. Webcast of the presentation and Q&A will be available in the Investor Relations se</description>
</item>
<item>
<title>Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-issue-first-quarter-2025-130000283</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-issue-first-quarter-2025-130000283</guid>
<pubDate>Fri, 25 Apr 2025 13:00:00 GMT</pubDate>
<description>BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (internat</description>
</item>
<item>
<title>Anika Reports Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-fourth-quarter-full-200500102</link>
<guid isPermaLink="true">https://6ix.com/company/anika-therapeutics-inc/news/anika-reports-fourth-quarter-full-200500102</guid>
<pubDate>Wed, 12 Mar 2025 20:05:00 GMT</pubDate>
<description>Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIR</description>
</item>
</channel>
</rss>